Portfolio Overview

This true example of a powerful multiplex signature involves a 634–probe set signature that can identify patients at high-risk for recurrence and/or high risk for cancer-related death.

Almac have identified a prognostic gene expression biomarker that prospectively identifies potential metastatic disease in prostate cancer patients.

Almac has identified and validated a powerful gene expression biomarker which identifies a molecular subgroup of patients who may benefit from anti-angiogenic therapy following standard of care chemotherapy.

Almac has developed a gene expression assay to predict outcomes following treatment with DNA damaging drugs such as Anthracycline and Cyclophosphamide, novel DNA-damaging therapeutics such as PARP inhibitors as well as Immuno-Oncology agents.

Almac’s gene expression biomarker utilised to predict response to EMT targeted agents across numerous disease indications which may be affected by the EMT pathway aberrations.ac has identified and validated a powerful gene expression biomarker which identifies a molecular subgroup of patients who may benefit from anti-angiogenic therapy following standard of care chemotherapy.

This gene expression based assay identifies a molecular subgroup of cancers that exhibit activation of immune checkpoint proteins such as PD-L1 and ID01, which results in immune system evasion and cancer cell survival.